Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06188442

Superiority of On-demand PrEP Versus PEP on Using Doxycycline for Preventing STI in MSM

The goal of this clinical trial is to compare the effectiveness of doxycycline taken for on-demand pre-exposure prophylaxis (DoxyODPrEP) and its post-exposure use (DoxyPEP) in preventing bacterial sexually transmitted infections (STI), including chlamydia, gonorrhoea, and syphilis among men who have sex with men (MSM). The main questions it aims to answer are:

1. Is DoxyODPrEP superior to DoxyPEP? 2. Are both regimens safe? 3. Does the MSM community accept the use of doxycycline to prevent bacterial STI?

Participants will be asked to take doxycycline according to the study arm they are randomly assigned to, and attend regular clinical follow-ups during the 2-year observation period. Researchers will compare the bacterial STI incidences between the two groups to see if DoxyODPrEP is superior to DoxyPEP.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

About this study

Participants would be randomly assigned to either DoxyODPrEP or DoxyPEP arm, and be instructed to take doxycycline with the respective dosing schedule. They would be followed up for 24 months for nucleic acid amplification test (NAAT) and antibody tests against bacterial STI, namely chlamydia, gonorrhoea, and syphilis. The subjects and investigators would not be blinded due to its open-label nature, as the two arms' dosing schedules are different. Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex. Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex. At each clinic visit, urine, and pharyngeal and rectal swabs would be self-collected on-site by the participants following instructions. Pill count would be performed for each follow-up visit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • has had sex with another male in the past six months
  • normally reside in Hong Kong
  • can communicate in written and spoken Chinese or English
  • willing and able to give written informed consent
  • being willing and able to attend scheduled study clinic visits
  • at risk of STI (had condomless sex with more than one man in the past 12 months, history of STI diagnosis in the past 12 months, inclination to have condomless sex, and other HIV-PrEP-eligible criteria)

Exclusion criteria

  • Being allergic to tetracycline class medicines
  • Currently taking medications that are contraindicated with doxycycline
  • Using antibiotics for more than 14 days in the month preceding enrolment

Treatment and study plan

DoxyODPrEP

Drug

Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex

Other names: doxycycline on demand PrEP

DoxyPEP

Drug

Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.

Other names: doxycycline PEP

Primary outcomes

  1. Time to the first episode of gonorrhoea after the enrolment visit

    Time frame: Months 1 to 24

    Time to the first episode of gonorrhoea after the enrolment visit

  2. Time to the first episode of chlamydia after the enrolment visit

    Time frame: Months 1 to 24

    Time to the first episode of chlamydia after the enrolment visit

  3. Time to the first episode of syphilis after the enrolment visit

    Time frame: Months 1 to 24

    Time to the first episode of syphilis after the enrolment visit

Secondary outcomes

  1. Safety profile

    Time frame: Months 1 to 24

    Percentage of participants experiencing adverse events and the associated grades

  2. Acceptability of regimens

    Time frame: Months 1 to 24

    Percentage of participants accepted the regimen

  3. Retention

    Time frame: Months 1 to 24

    Percentage of participants remained during the follow-up period

  4. Time to the first episode of HIV after the enrolment visit

    Time frame: Months 1 to 24

    Time to the first episode of HIV after the enrolment visit

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Official study title

Superiority of On-demand Pre-exposure Prophylaxis Versus Post-exposure Prophylaxis on Using Doxycycline for Preventing Sexually Transmitted Infections in Men Who Have Sex With Men

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Jan 3, 2024
Registry last updated
Jun 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.